COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB PLUS SULFASALAZINE VERSUS TNF-Α INHIBITORS  AND SULFASALAZINE MONOTHERAPY IN REACTIVE ARTHRITIS: A 12-MONTH RANDOMIZED STUDY

dc.contributor.author	Akhmedov Khalmurad Sadullayevich, . Mullokulov Javohir Jamshid ugli,.
dc.date.accessioned	2025-11-13T15:12:37Z
dc.date.available	2025-11-13T15:12:37Z
dc.date.issued	2025
dc.identifier.citation	Toshkent	en_US
dc.identifier.uri	http://repo.tma.uz/xmlui/handle/1/2375
dc.description.abstract	Reactive arthritis (ReA) is a post-infectious spondyloarthritis characterized by arthritis, enthesitis, and extra-articular features. Conventional treatments such as sulfasalazine (SSZ) show modest benefit, while TNF -α inhibitors are effective but limited by cost and accessibility. Baricitinib, a JAK1/2 inhibitor, offers a novel oral therapeutic strategy, though evidence in ReA is scarce.	en_US
dc.language.iso	en	en_US
dc.subject	reactive arthritis, baricitinib, adalimumab, DAREA, BASDAI.	en_US
dc.title	COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB PLUS SULFASALAZINE VERSUS TNF-Α INHIBITORS AND SULFASALAZINE MONOTHERAPY IN REACTIVE ARTHRITIS: A 12-MONTH RANDOMIZED STUDY	en_US
dc.type	Article	en_US